NewcelX Ltd.
NCEL · XNASCIK 1783036fmd_052BNH6Z6X35SGJFG8A42JNSK4Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Dec 31, 2025, 14 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Research and development | 1 | 1 | 0 | 6 | 9 | 2 | 1 | 1 |
| Total operating expenses | 3 | 4 | 2 | 12 | 15 | 12 | 4 | – |
| Operating income | (3) | (4) | (2) | (12) | (15) | (3) | (2) | (3) |
| Interest expense | – | 0 | 0 | 0 | 0 | 0 | 0 | – |
| Other non-operating income (expense) | 0 | (0) | (0) | (0) | (1) | (0) | (5) | (6) |
| Income before taxes | – | – | – | – | – | (3) | (7) | – |
| Net income | (5) | (5) | (3) | (12) | (16) | (3) | (7) | (8) |
| Net income to common shareholders | – | – | – | – | (16) | 3 | 7 | 8 |